Study Summary
This trial is testing whether a single shock from an implantable cardioverter defibrillator (ICD) is best treated with medication, ablation, or no intervention.
- Ventricular Tachycardia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: 12 months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Standard medical therapy
1 of 2
Ventricular Tachycardia Ablation
1 of 2
Active Control
Experimental Treatment
75 Total Participants · 2 Treatment Groups
Primary Treatment: Ventricular Tachycardia Ablation · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 80 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Reddy, Vivek Y., Matthew R. Reynolds, Petr Neuzil, Allison W. Richardson, Milos Taborsky, Krit Jongnarangsin, Stepan Kralovec, Lucie Sediva, Jeremy N. Ruskin, and Mark E. Josephson. 2007. “Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa065457.
- Kheiri, Babikir, Mahmoud Barbarawi, Yazan Zayed, Michael Hicks, Mohammed Osman, Laith Rashdan, Htay Htay Kyi, et al.. 2019. “Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients with Implantable Cardioverter-defibrillators”. Circulation: Arrhythmia and Electrophysiology. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/circep.119.007600.
- Frankel, David S., Stavros E. Mountantonakis, Erica S. Zado, Elad Anter, Rupa Bala, Joshua M. Cooper, Rajat Deo, et al.. 2012. “Noninvasive Programmed Ventricular Stimulation Early After Ventricular Tachycardia Ablation to Predict Risk of Late Recurrence”. Journal of the American College of Cardiology. Elsevier BV. doi:10.1016/j.jacc.2012.01.026.
- Sapp, John L., George A. Wells, Ratika Parkash, William G. Stevenson, Louis Blier, Jean-Francois Sarrazin, Bernard Thibault, et al.. 2016. “Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drugs”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa1513614.
- Sapp, John L., George A. Wells, Ratika Parkash, William G. Stevenson, Louis Blier, Jean-Francois Sarrazin, Bernard Thibault, et al.. 2016. “Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drugs”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa1513614.
- Reddy, Vivek Y., Matthew R. Reynolds, Petr Neuzil, Allison W. Richardson, Milos Taborsky, Krit Jongnarangsin, Stepan Kralovec, Lucie Sediva, Jeremy N. Ruskin, and Mark E. Josephson. 2007. “Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa065457.
- Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K, Kralovec S, Sediva L, Ruskin JN, Josephson ME. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007 Dec 27;357(26):2657-65. doi: 10.1056/NEJMoa065457.
- Sanjaya Gupta 2018. "Initial Management of Patients Receiving a Single Shock (IMPRESS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03531502.
Frequently Asked Questions
Is this study's target demographic older than middle-aged?
"The age range that this clinical trial's organizers are looking for is between 18-80 years old." - Anonymous Online Contributor
How many people total are involved in this experiment?
"The listings on clinicaltrials.gov show that this study is still open to patient recruitment, with the last update being on October 13th, 2021. This trial was first posted on April 9th, 2018 and is set to admit 75 patients from a single site." - Anonymous Online Contributor
Are patients able to enroll in this clinical trial at this time?
"The most recent update on clinicaltrials.gov shows that this study is still looking for patients. The first posting was on April 9th, 2018 and the last update was October 13th, 2021." - Anonymous Online Contributor
How can I sign up for this clinical trial?
"Tachycardia, ventricular and being between 18-80 years of age are the prerequisites for enrolling in this clinical trial. Right now, there are approximately 75 people who fit these qualifications." - Anonymous Online Contributor